Cargando…

Reduction of therapeutic antibody self-association using yeast-display selections and machine learning

Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery and early-stage optimization. Here, we report a h...

Descripción completa

Detalles Bibliográficos
Autores principales: Makowski, Emily K., Chen, Hongwei, Lambert, Matthew, Bennett, Eric M., Eschmann, Nicole S., Zhang, Yulei, Zupancic, Jennifer M., Desai, Alec A., Smith, Matthew D., Lou, Wenjia, Fernando, Amendra, Tully, Timothy, Gallo, Christopher J., Lin, Laura, Tessier, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704398/
https://www.ncbi.nlm.nih.gov/pubmed/36433737
http://dx.doi.org/10.1080/19420862.2022.2146629
_version_ 1784840046552023040
author Makowski, Emily K.
Chen, Hongwei
Lambert, Matthew
Bennett, Eric M.
Eschmann, Nicole S.
Zhang, Yulei
Zupancic, Jennifer M.
Desai, Alec A.
Smith, Matthew D.
Lou, Wenjia
Fernando, Amendra
Tully, Timothy
Gallo, Christopher J.
Lin, Laura
Tessier, Peter M.
author_facet Makowski, Emily K.
Chen, Hongwei
Lambert, Matthew
Bennett, Eric M.
Eschmann, Nicole S.
Zhang, Yulei
Zupancic, Jennifer M.
Desai, Alec A.
Smith, Matthew D.
Lou, Wenjia
Fernando, Amendra
Tully, Timothy
Gallo, Christopher J.
Lin, Laura
Tessier, Peter M.
author_sort Makowski, Emily K.
collection PubMed
description Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery and early-stage optimization. Here, we report a high-throughput protein engineering method for rapidly identifying antibody candidates with both low self-association and high affinity. We find that conjugating quantum dots to IgGs that strongly self-associate (pH 7.4, PBS), such as lenzilumab and bococizumab, results in immunoconjugates that are highly sensitive for detecting other high self-association antibodies. Moreover, these conjugates can be used to rapidly enrich yeast-displayed bococizumab sub-libraries for variants with low levels of immunoconjugate binding. Deep sequencing and machine learning analysis of the enriched bococizumab libraries, along with similar library analysis for antibody affinity, enabled identification of extremely rare variants with co-optimized levels of low self-association and high affinity. This analysis revealed that co-optimizing bococizumab is difficult because most high-affinity variants possess positively charged variable domains and most low self-association variants possess negatively charged variable domains. Moreover, negatively charged mutations in the heavy chain CDR2 of bococizumab, adjacent to its paratope, were effective at reducing self-association without reducing affinity. Interestingly, most of the bococizumab variants with reduced self-association also displayed improved folding stability and reduced nonspecific binding, revealing that this approach may be particularly useful for identifying antibody candidates with attractive combinations of drug-like properties. Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CS-SINS: charge-stabilized self-interaction nanoparticle spectroscopy; FACS: fluorescence-activated cell sorting; Fab: fragment antigen binding; Fv: fragment variable; IgG: immunoglobulin; QD: quantum dot; PBS: phosphate-buffered saline; V(H): variable heavy; V(L): variable light.
format Online
Article
Text
id pubmed-9704398
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97043982023-02-07 Reduction of therapeutic antibody self-association using yeast-display selections and machine learning Makowski, Emily K. Chen, Hongwei Lambert, Matthew Bennett, Eric M. Eschmann, Nicole S. Zhang, Yulei Zupancic, Jennifer M. Desai, Alec A. Smith, Matthew D. Lou, Wenjia Fernando, Amendra Tully, Timothy Gallo, Christopher J. Lin, Laura Tessier, Peter M. MAbs Report Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery and early-stage optimization. Here, we report a high-throughput protein engineering method for rapidly identifying antibody candidates with both low self-association and high affinity. We find that conjugating quantum dots to IgGs that strongly self-associate (pH 7.4, PBS), such as lenzilumab and bococizumab, results in immunoconjugates that are highly sensitive for detecting other high self-association antibodies. Moreover, these conjugates can be used to rapidly enrich yeast-displayed bococizumab sub-libraries for variants with low levels of immunoconjugate binding. Deep sequencing and machine learning analysis of the enriched bococizumab libraries, along with similar library analysis for antibody affinity, enabled identification of extremely rare variants with co-optimized levels of low self-association and high affinity. This analysis revealed that co-optimizing bococizumab is difficult because most high-affinity variants possess positively charged variable domains and most low self-association variants possess negatively charged variable domains. Moreover, negatively charged mutations in the heavy chain CDR2 of bococizumab, adjacent to its paratope, were effective at reducing self-association without reducing affinity. Interestingly, most of the bococizumab variants with reduced self-association also displayed improved folding stability and reduced nonspecific binding, revealing that this approach may be particularly useful for identifying antibody candidates with attractive combinations of drug-like properties. Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CS-SINS: charge-stabilized self-interaction nanoparticle spectroscopy; FACS: fluorescence-activated cell sorting; Fab: fragment antigen binding; Fv: fragment variable; IgG: immunoglobulin; QD: quantum dot; PBS: phosphate-buffered saline; V(H): variable heavy; V(L): variable light. Taylor & Francis 2022-11-26 /pmc/articles/PMC9704398/ /pubmed/36433737 http://dx.doi.org/10.1080/19420862.2022.2146629 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Makowski, Emily K.
Chen, Hongwei
Lambert, Matthew
Bennett, Eric M.
Eschmann, Nicole S.
Zhang, Yulei
Zupancic, Jennifer M.
Desai, Alec A.
Smith, Matthew D.
Lou, Wenjia
Fernando, Amendra
Tully, Timothy
Gallo, Christopher J.
Lin, Laura
Tessier, Peter M.
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
title Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
title_full Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
title_fullStr Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
title_full_unstemmed Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
title_short Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
title_sort reduction of therapeutic antibody self-association using yeast-display selections and machine learning
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704398/
https://www.ncbi.nlm.nih.gov/pubmed/36433737
http://dx.doi.org/10.1080/19420862.2022.2146629
work_keys_str_mv AT makowskiemilyk reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT chenhongwei reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT lambertmatthew reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT bennettericm reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT eschmannnicoles reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT zhangyulei reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT zupancicjenniferm reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT desaialeca reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT smithmatthewd reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT louwenjia reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT fernandoamendra reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT tullytimothy reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT gallochristopherj reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT linlaura reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning
AT tessierpeterm reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning